Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. - Giovannoni G; Kappos L; de Seze J; Hauser SL; Overell J; Koendgen H; Manfrini M; Wang Q; Wolinsky JS (European journal of neurology, 2022)